entertainment -WSS

entertainment

author：comprehensive 2025-10-01 17:35:19 - browse：2475

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Trump's false claims about Georgia's 2020 election long debunked

explore

knowledge

WSS

Being 'nonadherent' patient made me a more empathetic doctor

Use doctors trained outside the U.S. to ease the physician shortage

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Beware reading your test results before your doctor does

Dexcom's push to bring CGM to type 2 diabetes patients

'Screen and refer' systems are hurting patients

focus

entertainment

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Drug repurposing or repositioning? The language matters

Trump's false claims about Georgia's 2020 election long debunked

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The boys, now 6, who are gene therapy’s ‘edge case’ problem

In Memoriam: Notable people who died in 2023

What affirmative action's end means to a medical student

Supreme Court strikes down use of affirmative action

An interview with Robert F. Kennedy Jr. on vaccines

focus

STAT wants to know your pick for a great summer read or listen

ActiGraph execs on goal of drug approvals with digital endpoints

The wait for US passports is creating travel purgatory and snarling summer plans

FDA approves first treatment for ultra

ActiGraph execs on goal of drug approvals with digital endpoints

Canadians with cystic fibrosis outlive Americans by a decade

Wikipedia

explore

knowledge

focus